20-Jun-2025 8:53 AM CST - Seeking Alpha J&J, AbbVie get EU endorsement for Imbruvica's expanded approval Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), endorsed a label expansion for its and AbbVie's (NYSE:ABBV) cancer drug, Imbruvica.
19-Jun-2025 11:02 PM CST - Investing Snacks Should You Buy AbbVie After Flat Finish? AbbVie stock danced a wild intraday tango on Tuesday, only to end up flat-footed at the closing bell. The day's price swing from $183.70 to $187.12 showed signs of life, but not enough to hold gains.
18-Jun-2025 1:06 PM CST - Yahoo Finance AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in migraine treatment. Over the last month, AbbVie's stock price remained relatively flat,
13-Jun-2025 3:28 AM CST - Yahoo Finance FDA approves label expansion of AbbVie hepatitis C therapy The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie's Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection.
11-Jun-2025 4:07 PM CST - Yahoo Finance FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis.
11-Jun-2025 1:36 AM CST - Seeking Alpha AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript All right. Let's get kick off our next session. Very privileged to have the entire management team of AbbVie here with us. Rob, thank you very much for being here, and welcome. Look, I'd say we're very encouraged by the engagement of the administration ...
Latest ABBV Trades by Congress Members
22-MAY-2025 - Josh Gottheimer, NJ (District 5) purchased between $1,001 and $15,000.
20-Jun-2025 8:53 AM CST - Seeking Alpha J&J, AbbVie get EU endorsement for Imbruvica's expanded approval Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), endorsed a label expansion for its and AbbVie's (NYSE:ABBV) cancer drug, Imbruvica.
19-Jun-2025 11:02 PM CST - Investing Snacks Should You Buy AbbVie After Flat Finish? AbbVie stock danced a wild intraday tango on Tuesday, only to end up flat-footed at the closing bell. The day's price swing from $183.70 to $187.12 showed signs of life, but not enough to hold gains.
18-Jun-2025 1:06 PM CST - Yahoo Finance AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in migraine treatment. Over the last month, AbbVie's stock price remained relatively flat,
13-Jun-2025 3:28 AM CST - Yahoo Finance FDA approves label expansion of AbbVie hepatitis C therapy The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie's Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection.
11-Jun-2025 4:07 PM CST - Yahoo Finance FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis.
11-Jun-2025 1:36 AM CST - Seeking Alpha AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript All right. Let's get kick off our next session. Very privileged to have the entire management team of AbbVie here with us. Rob, thank you very much for being here, and welcome. Look, I'd say we're very encouraged by the engagement of the administration ...
